ERBB2 and non-small cell lung carcinoma: Although pyrotinib has not been approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), and its global applicability remains to be established, it has shown encouraging therapeutic potential in HER2-mutant NSCLC.